- Timetable
- Download all abstracts
- Plenary Lectures
- MSSJ Special Program
- Award Lecture
- Symposium Sessions（Day1, Day2）
- Fundamental Sessions（Day1, Day3）
- Young Researchers' Sessions (Int'l)（Day1, Day3）
- Young Researchers' Sessions（Day1, Day3）
- Poster Presentations（Day1, Day2, Day3）
- Evening Workshop
- Corporate Program
Poster Presentations
Day 3, June 12（Wed.） Room P1 (Multipurpose Hall)・Room P2 (Conference Room 101+102)
- 3P-28
HLA Class I and II Presented Immunopeptidome in Melanoma cell line
(1Univ. Tokyo, 2KCC)
oYuko Nakamura1, Akiko Fukuda1, Aya Nakayama1, Yoko Chikaoka1, Taku Kouro2, Kayoko Tsuji2, Feifei Wei2, Tetsuro Sasada2, Takeshi Kawamura1
Neoantigens are a type of autoantigen peptide displayed in the MHC, but with somatic mutations observed only in cancer tissues. In humans, MHC also has the name HLA. There are two types of HLAs, which are referred to as class I, and II, depending on their function. Our group has been investigating the search for Neoantigens from HLA class I presented peptides using clinical samples of human colon cancer cells and pancreatic cancer. The method involves eluting peptides using immunoprecipitation, measuring them using mass spectrometry, comparing the obtained results to a database created by genome analysis, performing peptide identification, and narrowing down the search for Neoantigens among them.
In this presentation, we will show that peptides presented by HLA class II as well as class I were isolated from melanoma cell A375 using immunoprecipitation and identified and analyzed using mass spectrometry. Data analysis was performed in PEAKS STUDIO 11, and characteristic peptides were identified for both Class I and Class II. The top scores of the identified peptides were examined for binding between HLA Class I or II and peptides using HLA binding prediction algorithm, and the %rank scores indicated that many peptides showed Strong binding or Weak binding.